University of Texas

Recent Events

News & Analysis

company and university of texas - All News and Analysis

• Positron Corporation Acquires Exclusive License to Coronary Disease Reversal and Prevention Practice Management Program from the University of Texas

  - 2008-07-01

  HOUSTON -- Positron Corporation (OTC: POSC) (the "Company") announced today that it has acquired an exclusive license to a coronary disease reversal and prevention practice management program created by K. Lance Gould, M.D. and the University of Texas Health Science Center at Houston. "We are grateful to the University...

  Tags: Company, FINANCE, Houston, Positron Corp., SOFTWARE, University of Texas

• Delcath Expands Multi-Center Phase III Trial for Metastatic Melanoma

  - 2008-06-24

  Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the University of Texas Medical Branch at Galveston UTMB, part of the University of Texas System, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion PHP System for...

  Tags: Company, FDA, HEALTHCARE, patient, University of Texas

• Platina Energy Group, Inc. Acquires Enhanced Oil Recovery, Inc. from UTEK Corporation

  - 2008-04-04

  TAMPA, Fla., CHEYENNE, Wyo. & AUSTIN, Texas -- UTEK Corporation (AMEX:UTK) (LSE-AIM:UTK), a leading Open Innovation services company, and Platina Energy Group, Inc. (OTCBB:PLGT) (FWB:O5Y), an exploration and production strategic reserve company, are pleased to announce that Platina has acquired Enhanced Oil Recovery, Inc., a wholly owned subsidiary of UTEK,...

  Tags: Austin, Company, FINANCE, INTERNET, Investment, recovery, University of Texas

• BG Medicine Forms Research Collaboration with M.D. Anderson Cancer Center to Discover Serum Biomarkers for Breast Cancer Treatment Response

  - 2007-05-09

  WALTHAM, Mass. -- BG Medicine announced today that it has entered into a research collaboration with The University of Texas M. D. Anderson Cancer Center aimed at improving the treatment of breast cancer. Under this agreement, BG Medicine will apply its biomarker discovery technology to the analysis of clinical samples...

  Tags: collaboration, Company, patient, protein, University of Texas

• Chemokine Therapeutics Annouces Results of Preclinical Study Conducted by M. D. Anderson Cancer Center on Its Anticancer Drug CTCE-9908.

  - 2007-05-03

  VANCOUVER, BRITISH COLUMBIA, May 3, 2007 CCNMatthews via COMTEX -- Chemokine Therapeutics Corp. (the "Company") (TSX:CTI)(OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced the results of a study conducted by The University of Texas M. D....

  Tags: Company, HARDWARE, Mice, mouse, University of Texas

• Petro Resources Announces New Board Members

  - 2006-05-08

  Petro Resources Corporation (OTC: PRCT) announced that it has added two new members to its Board of Directors. The newly appointed Directors are Joe L. McClaugherty and Steven Pfeifer. Mr. Joe L. McClaugherty is a Senior Partner of McClaugherty & Silver, P.C., a full service firm engaged in...

  Tags: board, Company, University of Texas

• ZIOPHARM Oncology Announces ZIO-101 Phase I Data Presented at AACR-NCI-EORTC International Conference; Novel Organic Arsenic Evidences Both Safety and Activity

  - 2005-11-16

  PHILADELPHIA -- ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that ZIO-101, a novel organic arsenic, has demonstrated safety at doses approximately 25 times higher than the currently approved dose for arsenic trioxide, an inorganic arsenic, in an ongoing Phase I trial that has treated 11 patients to date at...

  Tags: Company, patient, University of Texas

• Xpention Genetics Appoints Chief Scientific Officer

  - 2005-05-03

  CONIFER, Colo. -- Xpention Genetics Inc. (OTCBB: XPNG) Chief Executive Officer, David Kittrell, appointed world class scientist, Dr. Zbigniew Walaszek as the Company's Chief Scientific Officer and Chairman of the Scientific Advisory Committee. Dr. Walaszek received his Ph.D. in Bio-Organic Chemistry at Silesia Technical University and received postgraduate training...

  Tags: Company, Dr., University of Texas

• AVANIR's Anthrax Antibody Data Presented at 2005 ASM Biodefense Research Meeting

  - 2005-03-22

  SAN DIEGO -- AVANIR Pharmaceuticals' (AMEX:AVN) anti-anthrax monoclonal antibodies have demonstrated an ability to protect against the most lethal form of anthrax toxins in animal models. Data from additional studies conducted by Johnny W. Peterson, Ph.D., of the University of Texas Medical Branch were presented today in a poster entitled...

  Tags: Avanir Pharmaceuticals, Company, Dr., HEALTHCARE, MARKETING, SOFTWARE, Strategy, toxin, University of Texas

• Akorn, Inc. Enters into an Agreement to License a Patent from the University of Texas M.D. Anderson Cancer Center

  - 2005-02-17

  BUFFALO GROVE, Ill. -- Akorn, Inc. (AMEX:AKN) today announced that it has entered into the agreement to license a patent entitled "M-EDTA Pharmaceutical Preparations of Uses Thereof" (the "Invention") and related technology rights invented by Issam I. Raad and Robert Sheretz. The license grants Akorn the exclusive rights to develop...

  Tags: agreement, Akorn Inc., Company, patent, patient, University of Texas